OR WAIT null SECS
March 19, 2024
Article
Metformin demonstrated a protective effect against new-onset geographic atrophy, which persisted and was more pronounced in individuals without diabetes.
March 14, 2024
Oral minocycline was not associated with a decrease in GA enlargement over 24 months, compared with the run-in phase, in a recent phase 2 nonrandomized trial.
February 29, 2024
Podcast
The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations in ophthalmology research.
February 08, 2024
In a new episode of New Insight with Veeral Sheth, MD, a trio of retina specialists host a well-rounded conversation on recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.
February 04, 2024
Data from the phase 2 METforMIN trial do not support the use of oral metformin for reducing the progression of geographic atrophy.
December 08, 2023
Chief among a flurry of clinical advances in retina disease this year were the FDA approvals of complement inhibitors for GA and a higher-dose aflibercept for diabetic retinopathy. What comes next?
November 14, 2023
Video
At AAO 2023, David Lally, MD describes results from the phase 2 ARCHER study and the potential benefit of intravitreal ANX007 for patients with GA.
November 13, 2023
Veeral Sheth, MD, MBA discusses the 3 improvements needed for the future of treating patients with geographic atrophy.
David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.
Veeral Sheth, MD, MBA discusses safety signals reported with the use of approved therapies for geographic atrophy and the importance of real-world datasets.